OVERVIEW
YNIOS PHARMA is leading a Critical Care preclinical program to demonstrate its effectiveness in modulating acute systemic inflammatory responses, protecting vital organs and promoting faster patient recovery.
These acute systemic inflammatory responses can also develop into different situations such as Septic Shock, Acute Ischemic Stroke, Acute Myocardial Infarction and organ transplantation.
YNIOS PHARMA business model is to create revenues from out-licensing. The current strategy aims at early out-licensing the assets under development when Phase I/II studies have demonstrated the safety and efficacy of the compound.
YNIOS PHARMA is a biotech founded in March 2022 by Philippe Van Wesepoel and Jean François Plucker, the same founders of biotech OLYS Pharma which develops topical neuro-cutaneous treatments. *
* Diabetic Peripheral Neuropathic Pain – Neuralgia of the trigeminocervical complex (Migraine) – Low back pain – Osteoarthritis – Irritable Bowel Syndrome – Bladder Pain Syndrome
THE FOUNDERS
MANAGEMENT
The founders are the Associate Directors of the company. They combine extensive experience in management, international business development, intellectual property, research and innovation, and partnership strategies.